Cell technologies. Your vision. Our expertise. Imagine the possibilities...

GE HealthcareLife Sciences

3

“GE Healthcare’s cell technology strategy is aimed at harnessing the vast potential in stem cell applications as part of an overall cellular science portfolio.

To this end, we are determined to lead the way by investing in a stronghold of expertise within the cell dimension. Today we offer customized solutions for cell-based assays, together with a sophisticated platform for high-content analysis. Plus, we are developing cellular assay products derived from human embryonic stem cells for use in drug discovery, development, and toxicity screening. We are also continuously expanding our portfolio of innovative solutions that can be utilized to grow the future of cell therapy.

I am also proud to have Dr. Stephen Minger, who directed the first group that banked an embryonic stem cell in the UK cell bank, as our head of research and development for GE Healthcare’s products for cell technology.

I am confident that, with the extensive expertise of our team, we will keep pushing the frontiers of science and technology forward to enable scientists and researchers to maximize the potential that lies within the cell.”

Dr. Konstantin Fiedler General Manager cell technologies

GE Healthcare

Uncover the potential that lies within the cell.

5

Basic Research Translational Research Clinical Trials Cell Therapy Cord Blood Banking

Process Optimization • Scale-up • QC/QA • cGMP

Basic Research Drug Discovery

Clinical Trials

Target Identif cation • Target Validation • Screening • Lead Optimization • Toxicity Testing

Density Gradient Media

WAVE Bioreactor™

2/10 and 20/50 systemsRes-Q™ 60 BMC Celution® 800/CRS*

AXP™ AutoXpress™ system

Cell Factory

Stem cellderived models

WAVE Bioreactor™

2/10 and 20/50 systems

You have the ideas. We have the technologies to help you bring them to life.

Stem cell biology opens exciting opportunities for breakthrough scientific and medical discovery, research, and application. With the breadth of GE Healthcare’s knowledge and experience in cell biology at your disposal, you can rely on our profound expertise to help you

to see, to fathom, and to achieve. With GE Healthcare by your side, you can push the frontiers of scientific discovery forward so that today’s platforms help achieve better drug discovery and therapy for all our tomorrows. Cell Expertise

“I believe there is one company capable of making a sustainable difference in the world of stem cell biology. That company is GE Healthcare, with its immense expertise, global resources, sophisticated research centers, and commitment to technological innovation. Today GE Healthcare not only has the capacity to develop cellular assay products derived from human stem cells, but also offers a sophisticated cell imaging platform and systems to grow the future of cell therapy. I believe we are truly at the cusp of realizing the defining power of human stem cells on the future of healthcare.”

Dr. Stephen Minger Cell TherapyDevelopment and production of cells for therapeutic use.

GE Healthcare provides tools to prepare and handle the cells (enrich, expand, process).

Drug Discovery and ResearchUnderstanding of disease mechanisms and testing of drug candidates.

GE Healthcare uses its cell biology expertise to provide cellular analysis tools and cells to test drug candidates.

Processing

Expansion Scale-up

Separation

Characterization Differentiation

Assay Development Engineering

Stem CellsIndustrial Scale Culture

Image Analysis Imaging

Bioinformatics

Purification

IN Cell Analyzer

* Available in Europe only

76

Your goals. Our customized services.Expand your capacity through Cell Factory.“We have been using batches of frozen cells from GE for several years now. The batches are always delivered on time, and consistently perform as well as we expect in the assays in which we use them. Having a reliable outsourcing option such as that provided by GE, in addition to our own in house capabilities, gives us the flexibility we need to deal with our ever changing cell requirements.”

Peter Stacey, Ph.D., Principal Scientist, Research Enabling Group, Pfizer, UK

Welcome to Cell Factory: a range of services to facilitate research using cell-based assays particularly for high-throughput and high-content screening. Cell Factory is designed to meet the particular needs of large-scale cell production and efficient assay development.

Cell Factory is built upon GE Healthcare’s leading position in high-content

screening and technological expertise in the preparation of bulk quantities of cryopreserved cells. Moreover, the application of Design for Six Sigma to all core processes ensures consistent quality and reliability.

Our high levels of service and operational excellence ensure consistently high user satisfaction.

SERVICE DESCRIPTION

Assay design Design and building of assays using commercial or customer reagents

Assay optimization Formatting of assays to customer criteria and metrics

Transient cell engineering Large-scale sensor or target expression with validation to customer specification

Stable cell engineering Sensor or target expression, selection of clones, and validation

Bulk cell culture Large-scale (> 109) cell expansion

Plate preparation Cells predispensed onto plates ready for HTS/HCA

Imaging and analysis Image acquisition, analysis, and data mining to customer requirements

Relevant. Reliable. Confident.A new era in safety screening with human cell models.“Now we can provide cells of reproducible nature and consistent subtype, and we know this because we are growing them day in, and day out.”

Dr. Stephen Minger

Building on our Cell Factory capability for bulk cell manufacturing, our key focus is the commercial production of cellular assay products derived from human embryonic stem cells (hES cells).

Earlier detection, or prediction, of toxicity problems could significantly reduce overall drug development costs. Cells derived from hES cells have similar attributes to their counterparts in the human body, making them much more relevant for the accurate prediction of

the pharmacological characteristics of a drug candidate than the animal cell models or in vitro tests currently used.

Cardiotoxicity and hepatotoxicity are the most common causes of drug safety liabilities. Thus, our initial focus is the derivation of functional cardiomyocytes and hepatocytes, to provide a reliable, industrial-scale supply of cells for safety screening of drug candidates.

98

Visualize. Analyze. Realize. The power to probe deeper with IN Cell Analyzer.“High content imaging technologies have become indispensable tools in the advancement of our understanding of how the human body works at the cellular level. These new research platforms provide the capacity to generate hundreds of times more scientifically valuable information than the conventional analysis technologies that are currently in use today.”

Anthony Davies, Director of High Content Research Facility, Department of Clinical Medicine, Trinity College Dublin

With the ability to see deeper comes the capacity to analyze, and ultimately to realize new insights . When yesterday you had sight, today you have insight with IN Cell Analyzer – a system that automatically extracts and analyzes quantitative data from cellular images.

The remarkable monitoring and analysis capabilities of IN Cell Analyzer allow you to comprehend functional biology at the cellular level: to probe complex signaling mechanisms and elucidate

molecular function in normal and disease states; to study cell behavior in depth; and to even screen for new targets and illuminate mechanisms of action or potential toxic profiles of drug candidates.

IN Cell Analyzer supports an amazing depth and breadth of investigation, while it ensures highly relevant and precise data. This means that you can be much more confident of your results and save valuable time and resources.

IN Cell Analyzer 2000Cell analysis just got easier

IN Cell Analyzer 2000 is an automated microscope that images and analyzes both fluorescently stained and unlabeled cells in a high-throughput format. Data is captured in both a spatial and temporal context.

• Live or fixed cells, tissues, and organisms.

• Remarkable imaging flexibility enabled by a wide range of objectives (2 to 100×) and an extraordinary 4 Mp imaging camera to allow subcellular resolution or whole well imaging.

• Microtiter plates or slides.

• Compatible with robotics for screening applications.

IN Cell Investigator Analysis SoftwareIntuitive. Adaptive. Powerful

IN Cell Analyzer is seamlessly supported with a comprehensive suite of analysis tools to maximize data extraction and understanding. Designed by biologists and configured to meet a range of skills and experience, IN Cell Investigator aligns the level of your expertise to the complexity of your assay, from preconfigured analysis routines to the creation of your own analysis methods.

• Ability to measure and analyze over 70 morphological and intensity parameters automatically.

• Conduct automated analyses and data visualization.

• Reanalyze stored data as hypotheses evolve.

IN Cell MinerLocate. Correlate. Communicate

Data is your asset. IN Cell Miner is the comprehensive data management system of the IN Cell Analyzer product suite. IN Cell Miner is based on an industry accepted data management system, EMC Documentum.

• A robust and scalable solution that allows you to visually organize and retrieve your project data easily.

• Compare existing data with past and future data or reanalyze data in the light of new information.

Your vision. Our solutions. The confidence to achieve clinical success.“We are re-educating and re-targeting the immune system with clinical trials to target cancer and HIV. With the help of the WAVE Bioreactor, we are able to easily produce engineered T cells at doses well above 1 × 1010. The Wave perfusion culture system allows high density culture of T lymphocytes and reduction of residuals, such as vectors used for gene transfer.”

Bruce L. Levine, Ph.D., Associate Professor at University of PennsylvaniaDirector, Clinical Cell and Vaccine Production Facility at University of Pennsylvania

GE Healthcare has a steadily growing range of innovative solutions that you can utilize to grow the future of cell therapy. These include systems to reliably process cord blood and bone marrow, enrich adipose derived stem cells, enrich mononuclear cells through density gradient media, and expand cells in suspension.

Ficoll-Paque™ PREMIUMFicoll-Paque PREMIUM products are sterile, ready–to-use density gradient media used to produce different density preparations of mononuclear cells from peripheral blood, bone marrow, and umbilical cord blood by density gradient centrifugation. All Ficoll-Paque PREMIUM products are manufactured according to GMP and ISO 13485:2003 standards and the recommendations of the United States Pharmacopeia.

WAVE Bioreactor 2/10 and 20/50 systems*

WAVE Bioreactor systems provide a robust process for manufacturing human suspension cells with perfusion in a single disposable Cellbag™ bioreactor. The expanded cells remain biologically functional and can be re-activated to produce high amounts of cytokines.

* WAVE Bioreactor system for clinical applications in cell therapy is for research use only and for use under IND or IDE cleared by FDA in US.

Manual Cell Separation

Automated Cell Expansion

Celution 800/CRSCelution 800/CRS System gives you real-time access to adipose-derived stem and regenerative cells (ADRCs). The system facilitates automated extraction, washing, and concentration of ADRCs. It is also capable of effectively preparing ADRC-enhanced fat grafts as well as collecting tissue and treating the tissue using the same procedures.

AXP AutoXpress systemAXP AutoXpress system is an automated, functionally closed, and sterile system for volume reduction of cord blood components. This system delivers consistently high recoveries of mononucleated cells (MNCs) from cord blood with or without the addition of HES. The AXP AutoXpress system is also capable of simultaneous processing of multiple cord blood units.

Automated Cell Processing Systems

Res-Q 60 BMCRes-Q 60 BMC (Bone Marrow Concentration) is a point-of-care system designed to provide high quality cell concentrates of bone marrow derived stem cells easily, consistently, and reliably from bone marrow aspirates.

StemSource 900/MBStemSource 900/MB Tissue Processing System is a sterile, closed system that automatically processes tissue to yield large numbers of diverse primary regenerative cell types for research use. High stem and regenerative cell yield delivers on average 4.6 × 107 nucleated cells from 100 g of tissue.

1110

For local office contact information, visit:www.gelifesciences.com/contact

GE Healthcare Bio-Sciences ABBjörkgatan 30751 84 UppsalaSweden

GE Healthcare UK LimitedAmersham Place, Little ChalfontBuckinghamshire, HP7 9NAUK

GE Healthcare Europe, GmbHMunzinger Strasse 5D-79111 FreiburgGermany

GE Healthcare Bio-Sciences Corporation800 Centennial Avenue, P.O. Box 1327Piscataway, NJ 08855-1327USA

GE Healthcare Japan CorporationSanken Bldg., 3-25-1, HyakuninchoShinjuku-ku, Tokyo 169-0073Japan

28-9800-88 AC 01/2011

GE, Imagination at work, and GE monogram are trademarks of General Electric Company.

Ficoll-Paque, Cellbag, and WAVE Bioreactor are trademarks of GE Healthcare companies.

All third party trademarks are the property of their respective owners.

The StemSource 900/MB Tissue Processing /System for research applications is distributed by GE Healthcare in the following countries: UK, Norway, Austria, France, Denmark, Switzerland, Germany, Sweden, Belgium, Netherlands, Luxemburg, North America, Canada, and Mexico. For countries not appearing on the list, please contact Cytori Therapeutics directly (www.Cytoritx.com).

The Celution 800/CRS System is distributed by GE Healthcare in the following countries: UK, Norway, Austria, France, Denmark, Switzerland, Germany, and Sweden. For countries not appearing on the list, please contact Cytori Therapeutics directly (www.Cytoritx.com).

©2011 General Electric Company - All rights reserved.First published October 2010.